Wall Street believes these three small companies have significant upside potential.
The clinical-stage biotech company received great news from the FDA.
The latest pundit take on the stock provided a good reason for bulls to snap it up.
Investors took profits a day after the clinical-stage biotech company's shares soared.
Breakthrough Results from Study C602 Soleno Therapeutics, Inc. (NASDAQ: SLNO), a trailblazer in the biopharmaceutical industry, recently unveiled its promising
Soleno announced positive top-line results for DCCR, its lead therapy.
These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.
March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company...
REDWOOD CITY, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company...